Iraqi Kurds seek independence through shady oil sales
One of Boeing's dreariest performers continues to be its highest-tech, most fuel-efficient airplane
Here's what some veteran Kremlin-watchers have to say
A rougher-than-expected quarterly loss gives Amazon bulls something to think about and may enable Amazon executives to press for slower expansion
After a lull, lenders scramble to keep up with demand
Ministry of Supply’s Aviator jacket combines the structure of a tailored garment with the functionality of a windbreaker
Some well-funded startups are betting the Internet can help reinvent shopping's least pleasant experience: the bra fitting
The Boston Celtics power forward, who filed for bankruptcy in 2010, says athletes need more business education
Millions of workers at American small businesses aren’t guaranteed any time off after the birth of a child
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million
Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.
Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."